Majorelle Laboratories
Prevent. Protect. Support.
Our expertise
Majorelle is a French pharmaceutical company specialising in women's health, urology and family health.
Our work is guided by one shared commitment: to prevent, protect and support patients, with solutions that meet their care needs and address wider public health challenges.
Building on our long-standing expertise in women's health, we now also bring our know-how to urology and family health. This is grounded in an in-depth understanding of these therapeutic areas, of the day-to-day practice of healthcare professionals, and of patients' needs.
Accessibility is at the heart of what we do: making treatments, medical devices and healthcare products that address essential needs as widely available as possible.
Our mission
Our purpose is to work in areas of healthcare where patient care, prevention and support play a central role: women's health, urology and family health.
We provide medicines, medical devices and healthcare products to exacting pharmaceutical standards: meeting patients' needs, supporting the proper use of our products, and helping to widen access to them.
Our history
The Laboratoire Majorelle story began in 2012 with the inauguration of the laboratory and the launch of Optilova, a 2nd generation continuous-use pill in France.
Optimizette, the first desogestrel pill to be covered by social security without any additional risks of DVT.
Majorelle becomes a key player in the sexual health sphere with the launch of the first treatment for erectile dysfunction to come in cream form (Vitaros 1, 2).
Majorelle becomes the birth control market leader.
Eden is launched as the first condom to be covered by social security with a prescription, and the Assanis and Maternov brands are acquired.
Majorelle is committed to the sexual health of young people and launches its Eden Gen range in combination with the Sextember campaign.
EDEN condoms are available in all pharmacies free of charge to under 26s.
